ClinicalTrials.gov had 404,637 registered interventional trials on file as of March 2025, and more than 80% of trials still fail to meet their original enrollment timeline, per a 2020 review of enrollment barriers. Enrollment delay drives more added cost and lost time in a clinical trial than any other single operational variable, with Phase III trial conduct now running $55,716 a day per Tufts CSDD's 2024 analysis. Site-level enrollment output has also declined through the 2010s. This roundup gathers sourced data on enrollment timelines, cost per day by phase and therapeutic area, screen-failure and dropout rates, site-level performance, how patients actually learn about open trials, who is accountable for recruitment across a sponsor's program, which recruitment strategies the current evidence actually supports, and how site-based and decentralized trial models differ in practice. Every figure in this piece traces to a named source and publication year, not a restated vendor-blog claim, and any figure that could not be independently verified during this research carries an explicit flag.
Key clinical trial enrollment statistics at a glance
Clinical trials miss their enrollment timeline more than 80% of the time, sites enrolled a median of just six participants each by the late 2010s, and Phase III trial conduct now runs $55,716 a day, the highest of any phase. This table pulls one headline figure from each major theme in this piece, with a named source and year for every row.
Clinical trial enrollment timelines and missed-deadline rates
Clinical trial recruitment has stretched from a median 13 months in 2008-2011 to 18 months in 2016-2019 for Phase III trials, and the industry-wide inter-trial interval sat at roughly 17 months in 2024, per IQVIA.
More than 80% of clinical trials fail to meet their original enrollment timeline, and that gap typically forces a study extension, added sites, or both, according to a 2020 review of enrollment barriers. The same review found that more than 40% of trials amend their protocol before the first subject visit, a change that adds roughly four months to the timeline. Average enrollment efficiency for Phase III and IV trials runs below 40%. That means most late-stage trials fall short of their planned enrollment pace. That 2020 review also found that 55% of terminated trials cited low accrual as the single highest reason for stopping the study. That finding shows enrollment shortfalls threaten a trial's survival, not just its schedule.
Enrollment duration has also grown over the past decade. A peer-reviewed analysis of 5,672 industry-sponsored Phase III trials found the median recruitment period rose from 13 months in 2008-2011 to 18 months in 2016-2019, a 38% increase.
More recent data suggests the trend has leveled off. IQVIA's Global Trends in R&D 2025 report found that enrollment duration rose between 2021 and 2023 but stabilized in 2024; the report describes it as the largest opportunity to improve trial cycle times. The same report defines the inter-trial interval as the time between successive trials in a development program and puts the 2024 figure at roughly 17 months, down from a 32-month peak during the 2022 pandemic period.
Cost per patient and per randomized patient by phase and therapeutic area
No primary source publishes an audited cost-per-randomized-patient figure broken out cleanly by phase and therapeutic area. The closest verified benchmark is Tufts CSDD's direct daily trial cost data, drawn from 447 protocols with budget data from 2016 to 2021 inflated to 2023 dollars. This section reports cost per day of trial conduct, the nearest defensible proxy, rather than an unverified per-patient number.
Tufts CSDD's 2024 white paper puts the mean direct cost to run a Phase II or Phase III trial at approximately $40,000 a day. Phase III carries the highest daily cost of any phase. Phase I, the least expensive of the four phases Tufts measured, still runs $7,829 a day, which means a schedule slip adds real cost even in the cheapest phase.
Cost per day also varies sharply by therapeutic area. Immunology and respiratory trials run the most expensive per day of the areas Tufts measured; cardiovascular and oncology trials run the least expensive of the group.
The same Tufts study estimates that a single day of trial delay costs sponsors roughly $800,000 in lost or delayed prescription sales. The researchers say this figure replaces an outdated $4 million to $5 million estimate that had circulated in the industry for more than 25 years.
Market-size estimates for clinical trial patient recruitment services vary widely by vendor methodology, so no single number should be read as a settled consensus. One industry analysis estimates the global market at $1.06 billion in 2025, growing to $2.29 billion by 2035, an 8.01% compound annual growth rate. Mordor Intelligence's 2025 estimate independently lands on the same $1.06 billion. At the other end of the spread, Roots Analysis values the same market at $11.8 billion in 2025, projecting $26.2 billion by 2035, an elevenfold gap that comes down to which services each firm counts.
Screen-failure and dropout rates in clinical trials
Screen-failure rates range from roughly 1 in 5 candidates in some solid-tumor trials to more than 2 in 5 in biomarker-gated Alzheimer's studies, and no single average figure applies across all therapeutic areas. A review of 50 Phase II and III genitourinary cancer trials conducted between 1999 and 2016 found screen-failure rates of approximately 20% to 30% overall. Rates varied by cancer type: prostate cancer trials screen-failed 26% of candidates (range 12% to 45%), kidney cancer trials 25% (range 21% to 29%), and bladder cancer trials 19% (range 4% to 28%).
More recent data from early Alzheimer's disease trials shows even wider variation. A 2025 analysis of biomarker-gated enrollment found that a ptau-181 biomarker cutoff screen-failed 36.2% of prescreened candidates in the ADNI cohort and 42.1% in the NACC cohort. Biomarker-gated neurology trials screen out a substantially higher share of candidates than genitourinary cancer trials, where screen-failure rates run roughly 20% to 30%.
Screen-failure rate depends heavily on therapeutic area and protocol design. Claims of one flat industry-wide dropout or retention rate are not supported by a verifiable primary source and are avoided in this piece.
Site-level enrollment performance: how many sites actually deliver
One in 10 investigator sites that are ready to recruit fails to enroll a single patient, and 48% of all sites selected for a trial either enroll nobody or under-enroll, per a Tufts CSDD analysis of nearly 16,000 investigative sites. The study, reported by Tufts CSDD's Kenneth Getz in Applied Clinical Trials in 2012, covered 151 Phase II and III global trials conducted between 2008 and 2010, with performance data supplied by 10 pharmaceutical companies and two contract research organizations. Non-enrollment varied by region: 13% of North American sites failed to enroll a single patient, against 7% in Western Europe and 20% in Latin America.
A higher figure, that about 27% of investigator sites cannot enroll a single qualified patient, circulates widely in industry content attributed to Tufts CSDD. No Tufts publication supporting that number could be located during fact-checking for this piece, and Tufts' own published site-level figure is the lower 11%, so treat the 27% claim with skepticism.
Site-level performance has also declined over time in the same 5,672-trial Phase III dataset spanning 2008 to 2019. Median enrolled participants per site fell from 7 in 2008-2011 to 6 in 2016-2019, a statistically significant decline. The median recruitment rate per site also fell, from 0.8 participants per site per month in 2012-2015 to 0.4 in 2016-2019, though the study reports that decrease as not statistically significant.
Nearly half of selected sites enrolling nobody or missing their target is a site-level performance problem, separate from trial-level enrollment timelines, and it is the specific gap addressed by the agencies that close enrollment gaps at underperforming sites.
How patients actually find clinical trials: recruitment channel data
Most people who actually hear about a clinical trial hear about it online, 67% versus just 7% through their own doctor, yet 58% say they would prefer to learn about a trial from a doctor in the first place. CISCRP's 2023 global Perceptions and Insights survey asked respondents where they had seen or heard about a clinical research study. Among the 3,810 respondents who had never participated in a trial but had heard about one in the past six months, 67% heard about it online and just 7% heard about it from their own doctor. Among the 7,459 respondents who had never participated in a trial, 58% said they would prefer to learn about a trial from a doctor, versus 46% who preferred an online source.
Within the online channel alone, based on the 2,538 respondents who heard about a trial online, social media accounted for 61% of that awareness, online ads for 29%, patient advocacy group websites for 20%, and government trial registries for 16%.
That gap, between doctors as the preferred source and social platforms as the actual one, is central to how healthcare marketers reach patients across today's most-used channels.
Patient recruitment strategies backed by outreach and channel data
Digital outreach, AI-assisted candidate matching, and patient-advocacy partnerships are the three patient-recruitment strategies with sourced evidence behind them: patients say they hear about trials online 67% of the time and from a doctor just 7% of the time, per CISCRP's 2023 survey. That gap is why digital channels carry the most weight of the three.
Digital outreach covers paid search, paid social, and purpose-built patient-matching platforms such as Antidote, which lets patients search open trials by condition and location and get pre-screened before a site ever sees their information. A recruitment ad for a regulated trial does not run the moment a sponsor approves the creative, which is why a compliant trial ad clears three separate reviews before launch: IRB, FDA, and the ad platform itself, each applying its own standard for what a patient-facing claim can say.
AI and electronic-health-record matching tools scan structured patient records against a trial's eligibility criteria to surface candidates a manual chart review would miss, particularly for indications with narrow biomarker or lab-value cutoffs. No verified adoption-rate or accuracy figure for this category appears in the sourcing behind this piece, so none is asserted here.
Patient-advocacy-group partnerships already account for a meaningful share of how patients find trials online. Advocacy group websites made up 20% of online trial awareness in CISCRP's 2023 survey, behind only social media at 61% and paid online ads at 29%. That makes an established advocacy partnership one of the more efficient channels a sponsor can add to a recruitment plan.
Smaller and startup sponsors without a paid-media budget at scale tend to lean harder on advocacy partnerships and existing patient registries. Both cost less to activate than a sustained paid-social or paid-search campaign, though no source in this research set publishes a comparative cost figure between the two approaches, so none is claimed here.
Patient mistrust of clinical research is a documented recruitment barrier in its own right, one that outreach strategy alone does not solve; no source in this research set quantifies a mistrust rate, so none is asserted here.
Recruitment and retention are separate disciplines. This page is scoped to how sponsors find and screen candidates, not to what keeps an enrolled participant in a study through its final visit, and no source in this research set publishes a retention statistic, so none is asserted here.
Recruitment vs. enrollment: what the terms actually measure
Recruitment and enrollment mark different points on the same funnel, and the federal rulebook behind ClinicalTrials.gov draws the line at informed consent. A person counts as enrolled under 42 CFR 11.10(a), the regulation that defines terms for ClinicalTrials.gov reporting, once they or their legally authorized representative agree to participate after completing the informed consent process. Candidates screened for eligibility who never join the study are not counted as enrolled. Recruitment covers everything before that point: identifying candidates, outreach, and eligibility screening.
defines a study's enrollment simply as the number of participants in it, with estimated enrollment as the target researchers need. The two terms are often used interchangeably in casual industry conversation, but they describe different stages of the same funnel. That is why the definition behind a figure matters as much as the figure itself when comparing a sponsor's internal recruitment-rate metric against a published enrollment benchmark.
That same informed-consent line also marks where accountability shifts from one party to another: sponsors, site investigators, and CROs each own a different side of the funnel it defines.
Who's responsible for patient recruitment: sponsors, sites, and CROs
Three parties share accountability for patient recruitment in a clinical trial: the sponsor, the site investigator, and the contract research organization, or CRO. The sponsor owns the enrollment target and budget, the site executes local outreach and screening, and a CRO, when a sponsor engages one, coordinates recruitment operations across multiple sites.
Sponsor accountability extends beyond the topline enrollment number. Since the Food and Drug Omnibus Reform Act (FDORA) took effect, sponsors running pivotal trials for many new drugs and devices must also submit a Diversity Action Plan describing how the trial's enrollment will reflect the population the product is meant to treat. That obligation sits squarely on the sponsor's side of the funnel rather than the site's. That requirement responds to a real gap: pivotal trials have historically enrolled populations that look different from the patients who eventually take the drug, which is why only 6% of pivotal trials matched US demographics in a 2025 analysis. Closing that gap is now explicitly the sponsor's job, not the site's.
At the site level, recruitment accountability is local and hands-on: identifying eligible patients from the practice's own patient base or referral network, running community outreach, screening candidates against the protocol, and walking each candidate through informed consent. A site can run a technically sound protocol and still under-enroll if its own outreach is too narrow. Roughly 1 in 10 investigator sites ready to recruit fails to enroll a single patient, per Tufts CSDD's analysis of nearly 16,000 sites. That is exactly the site-level failure this accountability split is meant to catch early.
A CRO coordinates recruitment operations across multiple sites at once, standardizing screening criteria, tracking enrollment pace site by site, and reallocating outreach budget toward sites that are converting candidates. The Tufts CSDD site-performance research behind this page's own site-level data drew on exactly that kind of CRO involvement: the underlying analysis of nearly 16,000 investigator sites used performance data supplied by 10 pharmaceutical companies and two contract research organizations. No source in this research set quantifies what share of active trials use a CRO for recruitment specifically, as opposed to a CRO's other functions such as data management or monitoring, so no percentage is asserted here.
Decentralized vs. site-based recruitment: what changes
A decentralized clinical trial replaces some or all of a patient's in-person site visits with remote alternatives: telehealth check-ins, local labs or mobile nursing visits for sample collection, and direct-to-patient drug shipment. That structural shift widens the pool of eligible patients to anyone within reach of a local lab, rather than anyone within driving distance of a single site.
Sponsors most often layer decentralized elements onto specific parts of a protocol, such as remote follow-up visits or at-home vital-sign monitoring, rather than converting an entire trial to a fully remote model. Procedures such as imaging or infusion still require an in-person visit, regardless of the recruitment model a sponsor chooses.
This page does not claim a comparative enrollment-speed or enrollment-cost advantage for either model. No source in this research set publishes a controlled comparison of decentralized versus site-based enrollment outcomes, and an unsupported number is not asserted here just because the comparison would be useful to a reader.
The mechanism is verifiable; the outcome is not, at least not yet. A decentralized protocol structurally removes the driving-distance constraint that limits a traditional site's catchment area, while a site-based protocol keeps every visit and every eligibility check under one roof with one care team. Sponsors choosing between the two models today are weighing a real trade-off between geographic reach and the operational simplicity of a single site, without a settled data point that says one wins.
Frequently asked questions about clinical trial enrollment and recruitment
What does patient recruitment mean in a clinical trial?
Patient recruitment covers everything that happens before a candidate joins a study: identifying potential participants, reaching out to them, and screening them against the trial's eligibility criteria. A person only counts as enrolled under 42 CFR 11.10(a), the regulation that defines terms for ClinicalTrials.gov reporting, once they or their legally authorized representative agree to participate after completing informed consent. Everything before that point, from the first outreach message to the final eligibility check, is recruitment, not enrollment.
Who is responsible for patient recruitment in clinical trials?
Three parties share the job. The sponsor owns the enrollment target, the budget, and, for many pivotal trials, an FDA-mandated Diversity Action Plan. The site investigator runs local outreach, screening, and informed consent. A contract research organization, when a sponsor engages one, coordinates recruitment operations across multiple sites, the same multi-company role behind Tufts CSDD's site-performance research, which drew on data from 10 pharmaceutical companies and two CROs.
How long does patient recruitment take?
Median Phase III enrollment duration rose from 13 months in 2008-2011 to 18 months in 2016-2019, a 38% increase, based on a peer-reviewed analysis of 5,672 industry-sponsored trials. IQVIA's Global Trends in R&D 2025 report defines the inter-trial interval as the gap between successive trials in a development program and puts the 2024 figure at roughly 17 months, down from a 32-month peak during the 2022 pandemic period. More than 80% of trials still miss their original enrollment timeline.
What percentage of clinical trials fail to meet enrollment targets?
More than 80% of clinical trials fail to meet their original enrollment timeline, per a 2020 review of enrollment barriers. The same review found that 55% of terminated trials cited low accrual as the single highest reason for stopping a study, and that more than 40% of trials amend their protocol before the first subject visit, a change that typically adds about four months to the timeline.
How do you calculate a clinical trial enrollment rate?
No primary source in this research set publishes a formal enrollment-rate formula. The working definition implicit in the field's own reporting is participants enrolled per site per month. That is the same metric behind the site-level decline this page documents: the median recruitment rate fell from 0.8 participants per site per month in 2012-2015 to 0.4 in 2016-2019, though the underlying study found that decrease was not statistically significant. Multiply that per-site rate by the number of active sites to estimate a trial's overall monthly enrollment pace.
What are the most effective patient recruitment strategies?
Digital outreach, AI and electronic-health-record-based candidate matching, and patient-advocacy partnerships are the three recruitment strategies with sourced evidence behind them. Digital outreach carries the most weight: patients say they hear about trials online 67% of the time and from their own doctor just 7% of the time, per CISCRP's 2023 survey. Within online channels specifically, social media accounts for 61% of that awareness, paid ads for 29%, and advocacy-group websites for 20%.
Is decentralized recruitment better than site-based recruitment?
No verified, controlled comparison of decentralized versus site-based enrollment speed or cost exists in the current research set, so neither model can be called definitively better. What differs structurally is reach: a decentralized trial swaps some site visits for telehealth, local labs, and direct-to-patient drug shipment, extending eligibility beyond a single site's driving-distance radius, while a site-based trial keeps every visit and eligibility check under one care team. The right choice depends on the protocol and patient population, not a settled data point.
What the enrollment data adds up to
Enrollment remains the single biggest lever on clinical trial cost and timeline, and sponsors are still missing enrollment targets on a clear majority of trials. More than four in five trials miss their original timeline, site-level performance declined across the 2010s, and Phase III trial conduct now costs $55,716 a day. Recruitment success depends as much on process, ownership, and channel choice as it does on budget. Who is accountable for the funnel, which strategies the evidence actually supports, and whether a site-based or decentralized model fits the protocol all shape whether a trial hits its enrollment target on time. Patients say they want to hear about trials from a doctor. In practice, a doctor is rarely the source they actually hear from. Every figure in this piece traces to a named, dated primary source, and any figure that could not be independently verified during this research is explicitly flagged as such.